PharmaSeq Receives Prestigious Government Grant
Monmouth Junction, NJ, August 19, 2003. PharmaSeq, Inc. announced today that it has received an SBIR Phase I grant from the Institute of Allergy and Infectious Diseases of the National Institutes of Health. The grant will fund a project entitled “Cystic fibrosis mutation screening test” for the development of ethnic group specific diagnoses for cystic fibrosis. Cystic fibrosis is one of the most lethal diseases of childhood. Under the grant, PharmaSeq will develop a DNA test for several mutations causing cystic fibrosis. The diagnostic test will be based on PharmaSeq’s patented technology for microtransponder-based assays.
Dr. Richard Morris, the Chief Executive Officer, said: “This grant represents an important milestone for the company, and confirmation that our technology has broad potential in rapidly identifying the components involved in diseases that can be caused by a large number of possible mutations.”
Dr. Wlodek Mandecki, President and Principal Investigator on the project, commented: “We are very pleased to receive the NIH grant. This proves that the potential of our technology is recognized by both our peers and the leading government research organization.”